Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Dual Assay Test Detects Colorectal Cancer

By LabMedica International staff writers
Posted on 16 Dec 2013
The combination of two proprietary assays into one blood test can achieve a much better detection rates and specificity for colorectal cancer. More...


Current diagnostic screening practices for colorectal cancer vary globally, from inviting at-risk groups to submit fecal occult blood tests to offering regular investigative colonoscopies. Studies have shown compliance rates of between 30% to 60% for fecal blood tests, likely due to the uncomfortable nature of the test and that less than 40% of people who were offered a colonoscopy screening actually attended.

An ongoing prospective study at hospitals associated with the Catholic University of Louvain (Belgium) has indicated that when combining two proprietary NuQ assays (VolitionRx; Namur, Belgium) into one test, doctors can achieve 85% detection rates at 85% specificity for colorectal cancer. The data also shows that Volition’s two-assay test can detect more than 50% of precancerous polyps. Each NuQ enzyme linked immunosorbent assay (ELISA) captures intact nucleosomes and labels a specific feature. Volition’s NuQ range of products is based on the Nucleosomics platform, which identifies and measures nucleosome structures in cell culture, serum, plasma or other biofluids.

Scientists at the University Hospital Bonn (Germany) have reported preliminary data from a 90 patient independent trial, later confirmed in a further 113 patients. This data demonstrated 75% detection rates at 70% specificity when using a single NuQ assay. The Belgian team confirmed these results using the same single assay, but when combining it with another nucleosome biomarker they achieved even better results. They have now analyzed 39 patients’ samples from the ongoing prospective trial, which includes both healthy patients and patients with benign colon disorders.

Hans Jørgen Nielsen, MD, DMSc, professor of surgical oncology at Hvidovre Hospital (Copenhagen, Denmark) said, “The 85% detection rate seen in this latest study is on par with rates achieved by fecal occult blood tests. If we could improve screening compliance by offering the public a simple, less intrusive test that is just as accurate, we could detect even more colorectal cancer cases in the earlier stages and survival rates could drastically improve.”

Related Links:

Catholic University of Louvain
VolitionRx
University Hospital Bonn 




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.